Cancer vaccine optimism
Moderna is climbing moderately on low volatility as its oncology vaccine pipeline takes center stage ahead of late-breaking data at a major cancer congress, with the stock near a 52-week high and the Bayer patent ruling already priced in.
Sources: https://bioquicknews.com/moderna-announces-late-breaking-data-to-be-presented-at-esmo-congress/, https://www.st
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works